Common stock, par value $0.0001 per share
- Symbol
- ASBP
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Aspire-Lakewood Holdings, Inc.
ASBPNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events Pursuant to requests from holders of the Company’s public warrants (the “Public Warrants”), Aspire Biopharma Holdings, Inc. (the “Company”) wanted to clarify the terms of the Company’s public warrants which trade under the symbol “ASPBW”. The Warrants were originally issued on February 23, 2022 in connection with the initial public offering of Power Up Acquisition Corp.…
Company context
We are an early-stage biopharmaceutical and supplements company. On February 17, 2025, we completed a merger with Aspire Biopharma, Inc. (“Old Aspire”) and changed our name from Power Up Acquisition Corp. to Aspire Biopharma Holdings, Inc. and became a Delaware corporation. The Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held company Puerto Rican corporation incorporated in September 2021.
Current securities
Recent company filings
Registered securities in this filing
Aspire Biopharma Holdings, Inc. · 8-K · Filed 2026-07-20
Warrants, each exercisable for one share of common stock
- Symbol
- ASBPW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events
Pursuant
to requests from holders of the Company’s public warrants (the “Public Warrants”), Aspire Biopharma Holdings, Inc.
(the “Company”) wanted to clarify the terms of the Company’s public warrants which trade under the symbol “ASPBW”.
The Warrants were originally issued on February 23, 2022 in connection with the initial public offering of Power Up Acquisition Corp.
which was the Company’s predecessor. The Warrants had an initial exercise price which was $11.50 per share subject to adjustment
in certain events including a consolidation of the Company’s outstanding shares. On January 16, 2026, the Company affected a reverse
stock split of 1 for 30 and on May 11, 2026, the Company effected an additional reverse split of its common stock in a ratio of 40-1.
As a result of the two reverse splits, the Warrants now have an exercise price of $13,800 per share and a ratio of 1,200 Warrants to
purchase one share of common stock.